FDA Approves Nexviazyme, Next-generation ERT for Late-onset Pompe

FDA Approves Nexviazyme, Next-generation ERT for Late-onset Pompe

302259

FDA Approves Nexviazyme, Next-generation ERT for Late-onset Pompe

The U.S. Food and Drug Administration (FDA) has approved Nexviazyme (avalglucosidase alfa), a next-generation enzyme replacement therapy for late-onset Pompe disease. The medication, administered by infusion into the bloodstream every two weeks, is approved for patients 1 year or older and is expected to be available in the U.S. in the coming weeks, according to its developer, Sanofi Genzyme. The recommended dose is based on body weight — 20 mg/kg for patients weighing at least 30…

You must be logged in to read/download the full post.